MNOV 10k is out. This was in it. I didn't realize they had this many drugs in their pipe line. Last one results are pending.
Indication
Clinical Study
Principal Investigator / Institution
/Funding Agency(s)
Status
Multiple Sclerosis
Primary and Secondary Progressive Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis
Robert J. Fox, M.D., M.S., FAAN
Cleveland Clinic
National Institute on Neurological Diseases and Stroke
MediciNova, Inc.
Ongoing
Addiction
Methamphetamine Dependence
Randomized Trial of Ibudilast for Methamphetamine Dependence
Keith Heinzerling, M.D., MPH
UCLA
National Institute on Drug Abuse
Ongoing
Opioid Dependence
Effects of ibudilast (MN-166), a glial activation inhibitor, on oxycodone self-administration in opioid abusers
Sandra D. Comer, Ph.D.
Columbia University/NYSPI
National Institute on Drug Abuse
MediciNova, Inc.
Ongoing
Alcohol Dependence
Development of Ibudilast (MN-166) as a Novel Treatment for Alcoholism
Lara Ray, Ph.D.
UCLA
National Institute on Alcohol Abuse and Alcoholism
Ongoing
Marijuana Dependence
Effect of Ibudilast on Marijuana Withdrawal and Relapse
Margaret Haney, Ph.D.
Columbia University/NYSPI
National Institute on Drug Abuse
Ongoing
Pain
Chronic Medication Overuse Headache
Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomised, Placebo-Controlled Pilot Study
Discipline of Pharmacology, University of Adelaide
MediciNova, Inc.
Results Pending
